Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707664 · ClinicalTrials.gov registry record · Phase 2
Sargramostim Use in COVID-19 to Recover Patient Health
A Phase 2 study, sponsored by Partner Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT04707664 is a Phase 2 study that has completed, run by Partner Therapeutics. The registered enrollment target is 600 participants.
The verdict
NCT04707664, a Phase 2 study, has completed, sponsored by Partner Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.
Interventions
- DRUG Placebo
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707664
The ClinicalTrials.gov registry entry for NCT04707664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Partner Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04707664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707664 about?
NCT04707664 is a clinical study titled "Sargramostim Use in COVID-19 to Recover Patient Health". The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or ...
What is the current status of trial NCT04707664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2021-04-27. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04707664?
The interventions under investigation include: Placebo (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT04707664?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.